A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Status:
Suspended
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Subjects with hematologic malignancies or recipients of a first allogenic or autologus
hematopoietic stem cell transplant, without any evidence or respiratory infection, will
receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be
evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4
dose levels tested
Phase:
Phase 1
Details
Lead Sponsor:
Pulmotect, Inc.
Collaborators:
Cancer Prevention Research Institute of Texas National Heart, Lung, and Blood Institute (NHLBI)